Characterisation of a murine model of the late asthmatic response.

BACKGROUND

The incidence of asthma is increasing at an alarming rate. While the current available therapies are effective, there are associated side effects and they fail to adequately control symptoms in all patient subsets. In the search to understand disease pathogenesis and find effective therapies hypotheses are often tested in animal models before progressing into clinical studies. However, current dogma is that animal model data is often not predictive of clinical outcome. One possible reason for this is the end points measured such as antigen-challenge induced late asthmatic response (LAR) is often used in early clinical development, but seldom in animal model systems. As the mouse is typically selected as preferred species for pre-clinical models, we wanted to characterise and probe the validity of a murine model exhibiting an allergen induced LAR.

METHODS

C57BL/6 mice were sensitised with antigen and subsequently topically challenged with the same antigen. The role of Alum adjuvant, glucocorticoid, long acting muscarinic receptor antagonist (LAMA), TRPA1, CD4 and CD8 T cells, B cells, Mast cells and IgE were determined in the LAR using genetically modified mice and a range of pharmacological tools.

RESULTS

Our data showed that unlike other features of asthma (e.g. cellular inflammation, elevated IgE levels and airway hyper-reactivity (AHR) the LAR required Alumadjuvant. Furthermore, the LAR appeared to be sensitive to glucocorticoid and required CD4 T cells. Unlike in other species studied, the LAR was not sensitive to LAMA treatment nor required the TRPA1 ion channel, suggesting that airway sensory nerves are not involved in the LAR in this species. Furthermore, the data suggested that CD8 T cells and the mast cell-B-cell - IgE axis appear to be protective in this murine model.

CONCLUSION

Together we can conclude that this model does feature steroid sensitive, CD4 T cell dependent, allergen induced LAR. However, collectively our data questions the validity of using the murine pre-clinical model of LAR in the assessment of future asthma therapies.